Stock AnalizDexCom (DXCM) earnings for the quarter ended September 2026: EPS beats estimates
DexCom reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at $0.73 against the analysts’ average forecast of $0.67, a beat of 8.3%.
Revenue for the quarter was $1.34 billion, up 11.2% from $1.21 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 4.7% on the first trading day after the report.
The last four quarters
DexCom has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $0.73 | $0.67 | +8.3% | +11% | +4.7% |
| Jun 2026 | $0.70 | $0.61 | +15.1% | +13% | +11.1% |
| Mar 2026 | $0.56 | $0.47 | +19.0% | +15% | +6.6% |
| Sep 2025 | $0.61 | $0.57 | +7.5% | +22% | −14.6% |
What comes next
Analysts expect EPS of $0.72 for the next quarter on average and $2.70 for the fiscal year ending December 31, 2026.
The average analyst price target is $98.58, 18% above the current price of $83.33.
Valuation and score
DexCom scores 3.4 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 32.8, and its intrinsic value under moderate assumptions is about 41% below the current market value. Full DexCom analysis with 10 years of financials
Frequently asked questions
What was DexCom’s EPS for the quarter ended September 2026?
$0.73 adjusted per share, against an analyst consensus of $0.67.
How much revenue did DexCom report?
$1.34 billion, up 11.2% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.